Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Should We Alter an Unborn Child's Sexual Orientation with Genetic Engineering?
Biotech & Bioprocessing Should We Alter an Unborn Child's Sexual Orientation with Genetic Engineering?

The notion of genetically engineering an unborn child's sexual orientation has stirred debates among ethicists, scientists, and religious groups. This discourse stems from the suggestion that, with advancements in scientific knowledge, it might be possible to determine an unborn child's

How Is Google Using AI to Revolutionize Global Health Outcomes?
Tech & Innovation How Is Google Using AI to Revolutionize Global Health Outcomes?

Google has long been at the forefront of technological innovation, and its efforts in the health sector are no exception. By leveraging advanced artificial intelligence (AI) capabilities, the tech giant aims to enhance global health outcomes through improved accessibility to quality health

GRObio Faces IP Conflicts and Investor Uncertainty Amidst Restructuring
Biotech & Bioprocessing GRObio Faces IP Conflicts and Investor Uncertainty Amidst Restructuring

GRObio, a spinout from the George Church Lab at Harvard University, has encountered significant hurdles lately. Founded in 2016, GRObio focuses on developing therapeutic proteins built on nonstandard amino acids (NSAAs). Despite its pioneering approach, the company is undergoing a period of

How Will the Genomic Data Protection Act Impact Consumers?
Management & Regulatory How Will the Genomic Data Protection Act Impact Consumers?

Ivan Kairatov is a Biopharma expert with extensive knowledge in technology and innovation within the industry and considerable experience in research and development. Today, we discuss the newly introduced Genomic Data Protection Act (GDPA) and its implications. Can you explain the main purpose of

Advances in Bioprinting: From Tissue Engineering to Neuro Research
Biotech & Bioprocessing Advances in Bioprinting: From Tissue Engineering to Neuro Research

Bioprinting has emerged as a revolutionary bioengineering technique that utilizes the principles of 3D printing to create tissue-like structures embedded with living cells. Since its inception in 1988, this technology has experienced tremendous growth, advancing from its original concept to today’s

Funding Freeze Halts Crucial Malaria Vaccine Trials Amidst Global Needs
Research & Development Funding Freeze Halts Crucial Malaria Vaccine Trials Amidst Global Needs

The recent halt of life-saving drug trials due to an unanticipated funding freeze by the U.S. government has created significant uncertainty and disruption in the fight against malaria, a disease that remains a major global health threat. This decision, stemming from an initiative by the Trump

Nematode's 46,000-Year Survival Explores Limits of Life and Science
Biotech & Bioprocessing Nematode's 46,000-Year Survival Explores Limits of Life and Science

The discovery of a nematode, known as Panagrolaimus kolymaensis, unearthed from the depths of the Siberian permafrost has astonished scientists. This microscopic worm managed to survive in a state of cryptobiosis for an astounding 46,000 years. Over this period, it remained suspended in a

Can Danaher Lead the Biopharma Sector With Innovations and Biosimilars?
Biotech & Bioprocessing Can Danaher Lead the Biopharma Sector With Innovations and Biosimilars?

As the landscape of biopharmaceutical manufacturing undergoes significant changes, Danaher Corporation stands at a pivotal crossroads with the potential to lead through its innovative strategies and products. At the TD Cowen Health Care Conference, Danaher President and CEO Rainer Blair emphasized

Are New Zealand's Health Data Protection Measures Sufficient Enough?
Management & Regulatory Are New Zealand's Health Data Protection Measures Sufficient Enough?

When a routine investigation by New Zealand authorities revealed alarming gaps in the protocols for managing health data, the country found itself grappling with an urgent and complex challenge. In an era where data breaches are becoming increasingly frequent and sophisticated, the protection of

Protagonist and Takeda's Rusfertide Shows Promise in Phase 3 Trial
Research & Development Protagonist and Takeda's Rusfertide Shows Promise in Phase 3 Trial

The collaborative effort between Protagonist Therapeutics and Takeda Pharmaceutical to develop rusfertide, an injectable drug aimed at treating polycythemia vera, has achieved a significant milestone. Polycythemia vera is a rare blood disorder marked by a proliferation of red blood cells that can

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later